Shire Plc American Depositary Shares (SHPG) 247.94 $SHPG
Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...
ANI Pharmaceuticals Acquires Vancocin® Capsules and Additional Vancomycin Assets from Shire
PR Newswire - Fri Aug 01, 3:30PM CDT
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) today announced that it has acquired the US rights for Vancocin® 125 mg and 250 mg capsules from Shire plc, a global biopharmaceutical company. In addition, ANI acquired from Shire approved ANDAs for the currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm ($45 million in 2013 market value, per IMS Health) and vancomycin hydrochloride oral solution 250 mg and 500 mg. ANI paid $11 million in cash for the rights to Vancocin® together with existing inventories on hand. Following a transition period, ANI intends to launch Vancocin® capsules under its own label during the fourth quarter of 2014. The transaction is immediately accretive and sales of Vancocin® capsules are expected to generate approximately $5.4 million in revenues and $4 million in non-GAAP EBITDA annually.
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
Tax Inversion: Boon for Firms & Investors, Bane for U.S. Treasury - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:41AM CDT
The U.S. Treasury may lose $19.5 billion over the next decade due to tax inversion.
Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Marketwire - Wed Jul 30, 5:04PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.
Merck 2Q profit more than doubles
By LINDA A. JOHNSON - AP - Tue Jul 29, 10:45AM CDT
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double second-quarter profit, improve its profit forecast and top analysts' expectations.
Shire Announces Award Recipients for 2014 Michael Yasick ADHD Scholarship
PRWeb - Tue Jul 29, 9:08AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the recipients of its 2014 Michael Yasick ADHD Scholarship. The program is for individuals in the United States diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) who are pursuing higher education at a college, vocational school, or technical school. Fifty-seven award recipients have been selected from 2,380 applicants across the United States. As a part of the scholarship application process, applicants completed an essay explaining how ADHD has impacted their lives and submitted letters of recommendation. Additional award selection criteria included involvement in community service, and volunteer and extracurricular activities.
Hospira Eyeing Bid For Danone Unit in Latest Tax Deal
at The Street - Mon Jul 28, 8:40AM CDT
America's unloved tax regime may be about to deliver another European takeover as Illinois-based Hospira reportedly is working on an offer worth about $5 billion for Danone's medical nutrition business.
Humira Still Key to AbbVie
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 25, 1:43PM CDT
AbbVie markets the planet's top-selling biotechnology drug, and the company's second-quarter results show no signs that Humira's sales pace is slowing. That's good news for AbbVie, but investors are right to wonder whether the company's...
AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 10:52AM CDT
AbbVie (ABBV) will provide additional details on the upcoming Shire acquisition this fall.
AbbVie Beats Earnings Views, Sees Slower Humira Gain
at Investor's Business Daily - Fri Jul 25, 10:46AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today....
AbbVie 2Q profit climbs 2.8 percent
AP - Fri Jul 25, 8:42AM CDT
NORTH CHICAGO, Ill. (AP) — Drugmaker AbbVie Inc.'s (ABBV) second-quarter profit increased nearly 3 percent and beat analysts' expectations, as sales soared for the world's top-selling drug, Humira.
Shire, ArmaGen Ink Licensing Agreeement for AGT-182 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 5:00PM CDT
Shire (SHPG) recently entered into a worldwide licensing and collaboration agreement with U.S. based privately-held biotechnology company, ArmaGen.
Will AbbVie (ABBV) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:58PM CDT
AbbVie Inc. (ABBV) is scheduled to report its second-quarter 2014 results before the opening bell on Jul 25.
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Why Corporate Inversion Is More Than a Political Punching Bag
at The Street - Wed Jul 23, 11:49AM CDT
There is definitely a corporate tax problem, but politicians are more concerned about creating an election issue than about creating a good solution.
Shire to spend about $225M on drug collaboration
By The Associated Press - AP - Wed Jul 23, 7:44AM CDT
The drugmaker Shire plans to spend about $225 million in a joint effort with a privately held, U.S. firm to develop a potential treatment for the rare and life-threatening genetic disorder Hunter syndrome.
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
PR Newswire Europe - Wed Jul 23, 6:01AM CDT
LEXINGTON, Massachusetts, July 23, 2014 /PRNewswire/ --
Salix, Actavis Lead IBD 50 Drug Earnings This Week
at Investor's Business Daily - Sat Aug 02, 7:02AM CDT
Salix Pharmaceuticals (SLXP), which announced its tax inversion merger last month, will be among several IBD 50 drug stocks to report earnings this week. In July, Salix announced plans to merge with Italy's Cosmo Pharmaceuticals' Irish subsidiary,...
ANI Pharmaceuticals Acquires Vancocin® Capsules and Additional Vancomycin Assets from Shire
PR Newswire - Fri Aug 01, 3:30PM CDT
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) today announced that it has acquired the US rights for Vancocin® 125 mg and 250 mg capsules from Shire plc, a global biopharmaceutical company. In addition, ANI acquired from Shire approved ANDAs for the currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm ($45 million in 2013 market value, per IMS Health) and vancomycin hydrochloride oral solution 250 mg and 500 mg. ANI paid $11 million in cash for the rights to Vancocin® together with existing inventories on hand. Following a transition period, ANI intends to launch Vancocin® capsules under its own label during the fourth quarter of 2014. The transaction is immediately accretive and sales of Vancocin® capsules are expected to generate approximately $5.4 million in revenues and $4 million in non-GAAP EBITDA annually.
3 Eye-Catching Health Care Stocks this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:44AM CDT
These stocks are well positioned in today’s market environment.
Tax Inversion: Boon for Firms & Investors, Bane for U.S. Treasury - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 10:41AM CDT
The U.S. Treasury may lose $19.5 billion over the next decade due to tax inversion.
Trimel Provides Corporate Update and Second Quarter 2014 Financial Results
Marketwire - Wed Jul 30, 5:04PM CDT
Trimel Pharmaceuticals Corporation (TSX: TRL) today provided an overview of its corporate accomplishments and reported financial results for the three month period ended June 30, 2014.
Merck 2Q profit more than doubles
By LINDA A. JOHNSON - AP - Tue Jul 29, 10:45AM CDT
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double second-quarter profit, improve its profit forecast and top analysts' expectations.
Shire Announces Award Recipients for 2014 Michael Yasick ADHD Scholarship
PRWeb - Tue Jul 29, 9:08AM CDT
Shire plc (LSE: SHP, NASDAQ: SHPG) announces the recipients of its 2014 Michael Yasick ADHD Scholarship. The program is for individuals in the United States diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) who are pursuing higher education at a college, vocational school, or technical school. Fifty-seven award recipients have been selected from 2,380 applicants across the United States. As a part of the scholarship application process, applicants completed an essay explaining how ADHD has impacted their lives and submitted letters of recommendation. Additional award selection criteria included involvement in community service, and volunteer and extracurricular activities.
Hospira Eyeing Bid For Danone Unit in Latest Tax Deal
at The Street - Mon Jul 28, 8:40AM CDT
America's unloved tax regime may be about to deliver another European takeover as Illinois-based Hospira reportedly is working on an offer worth about $5 billion for Danone's medical nutrition business.
Humira Still Key to AbbVie
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 25, 1:43PM CDT
AbbVie markets the planet's top-selling biotechnology drug, and the company's second-quarter results show no signs that Humira's sales pace is slowing. That's good news for AbbVie, but investors are right to wonder whether the company's...
AbbVie Q2 Earnings Top on Humira Sales, Shire In Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 10:52AM CDT
AbbVie (ABBV) will provide additional details on the upcoming Shire acquisition this fall.
AbbVie Beats Earnings Views, Sees Slower Humira Gain
at Investor's Business Daily - Fri Jul 25, 10:46AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today....
AbbVie 2Q profit climbs 2.8 percent
AP - Fri Jul 25, 8:42AM CDT
NORTH CHICAGO, Ill. (AP) — Drugmaker AbbVie Inc.'s (ABBV) second-quarter profit increased nearly 3 percent and beat analysts' expectations, as sales soared for the world's top-selling drug, Humira.
Shire, ArmaGen Ink Licensing Agreeement for AGT-182 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 5:00PM CDT
Shire (SHPG) recently entered into a worldwide licensing and collaboration agreement with U.S. based privately-held biotechnology company, ArmaGen.
Will AbbVie (ABBV) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:58PM CDT
AbbVie Inc. (ABBV) is scheduled to report its second-quarter 2014 results before the opening bell on Jul 25.
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Why Corporate Inversion Is More Than a Political Punching Bag
at The Street - Wed Jul 23, 11:49AM CDT
There is definitely a corporate tax problem, but politicians are more concerned about creating an election issue than about creating a good solution.
Shire to spend about $225M on drug collaboration
By The Associated Press - AP - Wed Jul 23, 7:44AM CDT
The drugmaker Shire plans to spend about $225 million in a joint effort with a privately held, U.S. firm to develop a potential treatment for the rare and life-threatening genetic disorder Hunter syndrome.
Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen
PR Newswire Europe - Wed Jul 23, 6:01AM CDT
LEXINGTON, Massachusetts, July 23, 2014 /PRNewswire/ --
